Clene Inc. (CLNN)
NASDAQ: CLNNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CLNN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $50.69M
- EPS (TTM)
- -$2.30
- Dividend yield
- None
- 52-week range
- 3.02 – 10.84
- Day range
- 3.30 – 3.60
- Volume / Avg
- 143.56K / 115.06K
- Beta
- —
- Shares outstanding
- 14.40M
52-week range
CLNN stock today
Shares of Clene (CLNN) finished higher on Nov 20 at $3.52, a gain of 0.57% or $0.02 per share, versus the S&P 500's 3.70% decline. Shares are 67.5% below their 52-week high of $10.84, set on Nov 28, 2025 and 16.6% above the 52-week low of $3.02, near the bottom of the past year's range. CLNN is down 40.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 62.0%.
Clene has posted a net loss over the last twelve months (EPS of -$2.30), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Clene
Company profileClene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. It develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Robert Etherington MBA
- Headquarters
- Salt Lake City, UT
- Employees
- 76
- Website
- clene.com
Financial highlights
Full financialsIn fiscal 2025, Clene generated $200,000 in revenue, down 41.5% from fiscal 2024, its first annual decline since 2024. Clene reported a net loss of $26.2 million, compared with a loss of $39.4 million a year earlier. Gross margin was 78.5% (down from 79.5%) and operating margin -11541.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $200.00K | $342.00K | $654.00K | $473.00K | $723.00K |
| Growth | -41.52% | -47.71% | +38.27% | -34.58% | +250.97% |
| Net income | $-26.17M | $-39.40M | $-49.50M | $-29.92M | $-9.74M |
| EPS (diluted) | — | — | — | — | $-0.16 |
Analyst forecast
ForecastConsensus (5 analysts)
none
Avg. price target
$32.20+814.77%
- Strong buy 1
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $0.05 vs $-0.46
- Surprise
- +110.87%
CLNN news
All CLNN news- Clene Inc. Reports Third Quarter 2026 Financial Results and Recent Operating HighlightsNasdaq
- Clene Reports Third Quarter 2026 Financial Results and Recent Operating HighlightsGlobeNewswire
- Clene Seeks FDA Clearance For CNM-Au8 Following ALS Clinical ResearchNasdaqCLNN, SUN
- Clene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALSGlobeNewswire
Clene peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ALDXAldeyra Therapeutics Inc. | 0.84 | +16.39% | $50.70M | vs CLNN |
| ACRVAcrivon Therapeutics Inc. | 1.15 | -17.86% | $49.35M | vs CLNN |
| LFVNLifevantage Corporation | 4.15 | -15.13% | $52.63M | vs CLNN |
| XBITXBiotech Inc. | 1.73 | +2.98% | $52.74M | vs CLNN |
| HRTXHeron Therapeutics Inc. | 0.2525 | -4.39% | $48.04M | vs CLNN |
| RFLRafael Holdings Inc. Class B | 0.9197 | +2.19% | $47.99M | vs CLNN |
| ONCYOncolytics Biotech Inc. | 0.3501 | -10.37% | $47.66M | vs CLNN |
| CTORCitius Oncology Inc. | 0.5035 | -10.95% | $53.25M | vs CLNN |
Indexes, lists and sector
Clene stock FAQ
What is Clene's stock price today?
CLNN last traded at $3.52 as of Nov 20, 4:00 PM EST, up 0.57% on the day. Prices are delayed at least 15 minutes.
Does Clene pay a dividend?
No. Clene does not currently pay a regular cash dividend.
Who is Clene's CEO?
Mr. Robert Etherington MBA is the chief executive officer of Clene Inc., which has about 76 employees.
Has CLNN ever split its stock?
Yes. The most recent CLNN stock split was a 1-for-20 split on Jul 11, 2024.
What is the CLNN 52-week high?
The 52-week high for CLNN is $10.84 and the 52-week low is $3.02. The stock is currently 67.5% below its high.